DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting

Information source: Sanofi
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Diabetes Mellitus, Type 2

Intervention: Insulin glulisine (Drug); Insulin glargine (Drug); Premixed insulin (Insulin Aspart 30/70 ) (Drug)

Phase: Phase 4

Status: Terminated

Sponsored by: Sanofi

Official(s) and/or principal investigator(s):
Clinical Sciences & Operations, Study Director, Affiliation: Sanofi


Primary Objective: To demonstrate non-inferiority of once daily injection of insulin glargine (Lantus) plus one injection of mealtime insulin glulisine (Apidra) at the main meal versus twice daily premixed insulin (NovoMix 30/70) based on the reduction of HbA1c percentage from baseline to endpoint. Secondary Objective:

- To determine treatment satisfaction (DTSQs/Diabetes Treatment Questionnaire - Status,

DTSQc/ Diabetes Treatment Questionnaire - change and ITSQ/Insulin Treatment

Satisfaction Questionnaire)

- To determine the mean HbA1c, FBG (Fasting Blood Glucose), prandial BG (Blood Glucose)

and proportion of patients with a HbA1c <7%

- To determine the effect on adverse events (e. g. symptomatic hypoglycemic events, weight

gain and injection site reactions)

- To determine the total insulin dose, average insulin glargine, insulin glulisine and

premixed insulin dosages.

Clinical Details

Official title: Better Acceptance of a Single Injection Apidra (Insulin Glulisine) Added to Once Daily Lantus (Insulin Glargine) Versus Twice Daily Premixed Insulin in a Real Life Use Setting

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Glycosylated Haemoglobin (HbA1c) Value

Self Measured Blood Glucose (SMBG)

Secondary outcome:

DTSQs (Diabetes Treatment Satisfaction Questionnaire - status)

DTSQc (Diabetes Treatment Satisfaction Questionnaire - change)

ITSQ (Insulin Treatment Satisfaction Questionnaire)

Hypoglycemic events

Adverse Events (excluding hypoglycemic events)


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion criteria:

- Patients with type 2 diabetes mellitus treated with insulin glargine once daily and

oral blood glucose lowering medication

- Patients with a HbA1c > 7%

- Patients with a FBG within range (4-7 mmol/L) at baseline, based on the mean of 3 FBG

values (measured 5x during the run-in phase, with the highest and lowest value excluded) Exclusion criteria:

- Patients treated with an insulin other than insulin glargine

- Patients with hypersensitivity to insulin glargine, insulin glulisine, biphasic

insulin aspart/insulin aspart protamine 30/70 or any of the excipients

- Patients with a (pre)proliferative retinopathy (an optic fundus examination should

have been performed within the 2 years prior to study entry)

- Pregnant or lactating women

- Patients who are unable to fill in the PRO (Patient Reported Outcomes) questionnaires

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Locations and Contacts

Sanofi-Aventis Administrative Office, Gouda, Netherlands
Additional Information

Starting date: January 2010
Last updated: May 27, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017